. (2023). Valsartan, Losartan and Irbesartan use in the USA, UK, Canada and Denmark after the nitrosamine recalls: a descriptive cohort study. Bmj Open, 13, e070985. http://doi.org/10.1136/bmjopen-2022-070985
heart failure
. (2023). Bariatric Surgery and Incident Heart Failure: a Propensity Score Matched Nationwide Cohort Study. Int J Cardiol. http://doi.org/10.1016/j.ijcard.2023.01.086
. (2022). Risk prediction of mortality for patients with heart failure in England: observational study in primary care. Esc Heart Fail. http://doi.org/10.1002/ehf2.14250
. (2021). Lower risk of hospitalization for heart failure, kidney disease and death with sodium-glucose co-transporter-2 inhibitors compared with dipeptidyl peptidase-4 inhibitors in type 2 diabetes regardless of prior cardiovascular or kidney disease. Diabetes Obes Metab, 23, 2207-2214. http://doi.org/10.1111/dom.14437
. (2021). Lower cardiorenal risk with sodium-glucose cotransporter-2 inhibitors versus dipeptidyl peptidase-4 inhibitors in patients with type 2 diabetes without cardiovascular and renal diseases: A large multinational observational study. Diabetes Obes Metab, 23, 75-85. http://doi.org/10.1111/dom.14189
. (2022). Serum potassium variability as a predictor of clinical outcomes in patients with cardiorenal disease or diabetes: a retrospective UK database study. Clin Kidney J, 15, 758-770. http://doi.org/10.1093/ckj/sfab225
. (2022). Changes in heart failure management and long-term mortality over 10 years: observational study. Open Heart, 9. http://doi.org/10.1136/openhrt-2021-001888